Now turning to Late-Stage Development. Net revenue in the quarter was $319 million, which is up $21 million from the fourth quarter levels and up 14.9% -- 14.8% rather from first quarter of last year. Sequential and year-on-year revenue growth was driven by the very strong performance of our Phase II-IV clinical development services. I'd also highlight that our revenues in central laboratory services increased year-on-year and sequentially in both reported dollars, as well as on a constant currency basis. Late-Stage Development operating margin was $72.4 million or 22.7% of revenue, that's up 270 basis points sequentially and 250 basis points from a year ago.Read the rest of this transcript for free on seekingalpha.com
Covance's CEO Discusses Q1 2012 Results - Earnings Call Transcript
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.